Market News / Story
Perspective Therapeutics, Inc. (CATX) Gets FDA Fast Track for PSV359 in FAP-Positive SFT
·
Perspective Therapeutics received FDA Fast Track Designation for PSV359 to treat adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. Material Details #DetailAI Analyst View1FDA Fast Track for PSV359Expedites development/review; can enable rolling review and potential accelerated pathways.2Target: FAP-positive SFTAddresses a rare cancer with limited options, a niche where approvals can be faster.3Ongoing Phase 1/2a…